论文部分内容阅读
我国生化制药企业有289家,产品品种达700余种(包括原料药和制剂),工业总产值110亿元,出口交货值超过1亿美元。我国能够生产氨基酸类、多肽与蛋白质类、多糖类、酶类、脂类、核酸及其衍生物类等生化原料药,主要出口产品包括肝素、玻璃酸、硫酸软骨素、甲壳质、尿激酶、胰酶、辅酶A和胱氨酸等。中国用于生产生化原料药的生物原料极为丰富,且许多生化原料药在今后相当长时间内还属于资源依赖性产品,我国发展生化原料药应以生物提取和纯化为主要生产方法,同时发展微生物发酵工程和基因重组等现代生物技术。
China’s biochemical pharmaceutical companies have 289 varieties of products amounted to more than 700 species (including APIs and preparations), the industrial output value of 11 billion yuan, the export delivery value of more than 100 million US dollars. China can produce biochemical raw materials such as amino acids, peptides and proteins, polysaccharides, enzymes, lipids, nucleic acids and their derivatives. The main export products include heparin, hyaluronic acid, chondroitin sulfate, chitin, , Trypsin, coenzyme A and cystine and the like. China’s biological raw materials for the production of biochemical bulk drugs is extremely rich, and many biochemical bulk drugs for a long time in the future also belong to resource-dependent products, the development of biochemical raw materials should be biological extraction and purification as the main production methods, while the development of microorganisms Modern biotechnology such as fermentation engineering and gene recombination.